Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 12/20 | 0.54 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778016 | 1.00 | DPP8 (0.54) | DPP8DPP7HDAC8DPP9DPP4 | |
| SCHEMBL4770230 | 0.88 | DPP8 (0.54) | DPP8DPP7HDAC8DPP9DPP4 | |
| SCHEMBL4770222 | 0.88 | DPP8 (0.54) | DPP8DPP7HDAC8DPP9DPP4 | |
| SCHEMBL4773116 | 0.81 | HDAC8 (0.64) | DPP8DPP7HDAC8DPP9DPP4 | |
| SCHEMBL4773129 | 0.81 | HDAC8 (0.64) | DPP8DPP7HDAC8DPP9DPP4 | |
| SCHEMBL4772506 | 0.76 | HDAC8 (0.64) | DPP8DPP7HDAC8DPP9DPP4 | |
| SCHEMBL4772498 | 0.76 | HDAC8 (0.64) | DPP8DPP7HDAC8DPP9DPP4 | |
| SCHEMBL4776599 | 0.73 | DPP8 (0.56) | DPP8DPP7HDAC8DPP9DPP4 | |
| SCHEMBL4911586 | 0.73 | DPP8 (0.56) | DPP8DPP7HDAC8DPP9DPP4 | |
| SCHEMBL20570474 | 0.73 | HDAC8 (0.69) | DPP8DPP7HDAC8DPP9DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
| CN-101282932-A | Carboxyamine compounds and their use in the treatment of HDAC dependent diseases | NOVARTIS AG (CH) | 2008-10-08 | — | — | CN | claimed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | DPP8 1164/4885DPP7 921/4885HDAC8 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.